Traeger (COOK) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good Speaker1 afternoon. Thank you for attending the Traeger First Quarter Fiscal twenty twenty five Earnings Conference Call. My name is Matt, and I'll be the moderator for today's call. All lines will be muted in the presentation portion of the call for an opportunity for questions and answers at the end. I'll now have to pass the conference over to our host, Nick Backus with Traeger. Nick, please go ahead. Speaker2 Good afternoon, eve ...

Trupanion (TRUP) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Trupanion First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please note that this event is being recorded. I would now like to turn the conference over to Gil Melchior, Director of Investor Relations. Please go ahead. Speaker1 Good afternoon, and welcome to Tupanion's first quarter twenty twenty five financial results conference call. Participating on t ...

BigBear.ai Holdings (BBAI) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the Big Bear AI Holdings Incorporated First Quarter twenty five Earnings Call and Webcast. At this time, all participants are in a listen only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce David Cronlow. Thank you, David. You may begin. Speaker1 Thank you all for joining today for our first quarter twenty twenty five earnings call. I'm joined today by our ...

Barfresh Food Group (BRFH) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and thank you for participating on today's first quarter twenty twenty five corporate update call for Barfresh Food Group. Joining us today is Barfresh Food Group's Founder and CEO, Ricardo Dele Coste and Barfresh Food Group's CFO, Lisa Roger. Following prepared remarks, we will open the call for your questions. The discussion today will include forward looking statements. Except for historical infor ...

Financial Data and Key Metrics Changes - A10 Networks reported first quarter revenue of $66.1 million, reflecting a 9% year-over-year increase [12] - Non-GAAP net income for the quarter was $15 million, or $0.20 per diluted share, compared to $12.7 million, or $0.17 per diluted share in the same quarter last year [15] - Gross margin for the first quarter was 80.9%, consistent with the company's target range of 80% to 82% [15] - Adjusted EBITDA was $19.5 million, representing 29.5% of revenue [15] Business Line Data and Key Metrics Changes - Enterprise revenue grew by 18% year-over-year, while service provider revenue increased by 3% [6][12] - On a trailing twelve-month basis, enterprise revenue increased by 12%, indicating a solid foundation for future growth [6] - Product revenue accounted for 54% of total revenue, while services revenue made up 46% [13] Market Data and Key Metrics Changes - North America showed relatively strong performance, while Asia Pacific results were impacted by a strong Q1 last year due to large infrastructure projects in Japan [13] - Overall market conditions have improved and stabilized, with service provider customer growth driven by demand for greater data center capacity [6][11] Company Strategy and Development Direction - A10 Networks is focusing on expanding its presence and capabilities with enterprise customers, particularly through the acquisition of ThreatX Protect to enhance its cybersecurity portfolio [8][10] - The company aims to address non-discretionary security and capacity requirements, positioning itself to benefit from the rise of AI and its associated demands [6][10] - A10 Networks continues to target gross margins of 80% to 82% and adjusted EBITDA margins of 26% to 28% for the full year [18] Management's Comments on Operating Environment and Future Outlook - Management noted that while there may be delays in order timing due to market conditions, these are expected to be temporary [6] - The company remains optimistic about its strategic position and believes it is well-positioned to outpace the market in terms of revenue growth and profitability as conditions stabilize [11][20] Other Important Information - Total deferred revenue increased by 8% to $152.7 million, reflecting confidence from customers in A10's solutions [14] - The company ended the quarter with $355.8 million in cash, cash equivalents, and marketable securities, significantly up from $195.6 million at the end of 2024 [16] Q&A Session Summary Question: Impact of tariffs on customer conversations - Management indicated that there is caution among customers regarding macroeconomic conditions, but spending patterns are not completely frozen [25][27] Question: Visibility on AI data center initiatives - Management noted that they have reasonable visibility into large AI build-outs, but companies are modulating their plans based on financials [28][29] Question: Anticipated revenue growth - Management expressed comfort with expectations of high single-digit revenue growth for the year, pending macroeconomic shifts [34] Question: Competitive landscape in AI-driven product portfolio - Management stated that competitive dynamics remain similar, with partnerships evolving as service providers build out AI data centers [35] Question: Growth in enterprise revenue - Management clarified that the growth in enterprise revenue was influenced by a soft Q1 last year, with multiple customers contributing to the increase [39] Question: Caution among service provider customers - Management acknowledged broad-based caution among service provider customers, although some are more aggressive in their spending [40][41] Question: Sales and marketing expenses - Management indicated that the decrease in sales and marketing expenses was a strategic decision to manage costs while investing in R&D [42] Question: Full year EBITDA target - Management remains confident in achieving an EBITDA margin of 26% to 28% despite potential fluctuations in input costs [46][47] Question: Diversification of contract manufacturing partners - Management is actively working on diversifying manufacturing partners to build a more resilient supply chain [49][50] Question: Exchange rate impacts - Management noted that while exchange rates can pose revenue risks, project timelines are typically not heavily influenced by short-term fluctuations [51][53] Question: Product refresh outlook - Management clarified that product refresh cycles are part of normal business operations and do not indicate a significant change in customer outlook [58][59] Question: Tariff impact on pricing negotiations - Management stated that any tariff impact would require discussions with customers to determine how to share the burden, but specifics are uncertain until more information is available [61][62]

GSI (GSIT) Q4 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Welcome to GSI Technologies Fourth Quarter and Fiscal Year twenty twenty five Results Conference Call. At this time, all participants are on a listen only mode. Later, we will conduct a question and answer session. At that time, we will provide instructions for those interested in entering the queue for the Q and A. Before we begin today's call, the company has requested that I read the following safe harbor statement. The matters discussed ...

GeoVax Labs (GOVX) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome everyone to the GeoVax First Quarter twenty twenty five Corporate Update Call. My name is Michelle, and I will facilitate today's call. With me are David Dodd, Chairman and CEO Mark Reynolds, Chief Financial Officer Mark Newman, Ph. D. Chief Scientific Officer Kelly McKee, MD, Miles per hour, Chief Medical Officer and John Sharkey, PhD, Vice President, Business Development. At this time, all participants a ...

Viavi Solutions (VIAV) Q3 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Viavi Solutions Fiscal Third Quarter twenty twenty five Earnings Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. At this time, I would like to turn the conferenc ...

Financial Data and Key Metrics Changes - The company reported total revenues of $74.1 million for Q1 2025, a 61% increase compared to $46 million in Q1 2024 [19] - Net sales revenue for IBSRELA was $44.4 million, reflecting a 57% increase year-over-year [19] - Exposa generated net sales revenue of $23.4 million, up approximately 55% from $15.2 million in the same quarter last year [19][21] - The company recorded a net loss of approximately $41.1 million or $0.17 per share, compared to a net loss of $26.5 million or $0.11 per share in the prior year [23] Business Line Data and Key Metrics Changes - IBSRELA experienced strong prescription demand, with one of the highest prescription demand quarters to date [6] - Exposa grew by 30% year-over-year when excluding a one-time gross to net adjustment for return reserve release [7][21] - The gross to net deduction for IBSRELA was 34.8%, expected to improve throughout the year [20] Market Data and Key Metrics Changes - The IBS C market traditionally contracts in Q1, which was observed this year, but the company remains optimistic about recovery in subsequent quarters [31] - The dialysis market is undergoing significant disruption due to the loss of Medicare Part D coverage for phosphate-lowering therapies, impacting Exposa's market dynamics [8] Company Strategy and Development Direction - The company is focused on driving strong commercial execution for IBSRELA and navigating access complexities for Exposa [10] - The strategic imperatives include raising awareness of IBSRELA and positioning it as a first-line treatment for appropriate patients [13] - The company aims to achieve peak annual net sales revenue of over $1 billion for IBSRELA and $750 million for Exposa [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IBSRELA and Exposa, citing strong patient demand and effective commercial strategies [5][10] - The company is closely monitoring market dynamics and will provide further updates as the landscape evolves [9] - Management remains committed to building long-term value for shareholders despite current market challenges [10] Other Important Information - The company received a $5 million milestone payment from a partner in China following the approval of a cannabinoid for hyperphosphatemia [22] - Research and development expenses increased to $14.9 million, reflecting greater engagement with scientific and medical communities [22] Q&A Session Summary Question: Expectations for the IBS C market improvement in Q2 - Management expects the IBS C market to improve as the year progresses, based on strong prescription demand observed in Q1 [31][32] Question: Details on the return reserve and its impact - The return reserve was deemed unnecessary due to zero returns and limited bottles in distribution, leading to modest improvements in gross to net going forward [29][30] Question: Insights on the Q1 contraction and its differences from previous years - The contraction is consistent with historical trends, but the company remains optimistic about future growth [35][37] Question: Long-term gross to net targets and updates on the China launch - Long-term guidance for gross to net is expected to be around 30% plus or minus 5% [40] Question: Discrepancies between reported revenue and script data for IBSRELA - Management acknowledged fluctuations in scripts and emphasized the importance of focusing on guidance rather than individual quarter performance [48][50] Question: Metrics for assessing the expanded field force's impact - Key metrics include increases in activity, new riders, and new/refill prescriptions, all of which showed positive trends in Q1 [56][57] Question: Updates on the Kidney Patient Act and potential external asset acquisitions - The Kidney Patient Act is viewed as a call option, and the company is actively pursuing external assets in renal and GI spaces [102][104]

Cerus (CERS) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Seres Corporation First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tim Lee, Seres' Head of Investor Relations ...